© 1996 American Heart Association, Inc.
Articles |
Measurement of the Free Form of TFPI Antigen in Hyperlipidemia
Relationship Between Free and Endothelial Cell–Associated Forms of TFPI
From the National Cardiovascular Center, Research Institute (T.K., K-i.E., M.H.-S., A.Y., H. Kato) and Hospital (Division of Atherosclerosis and Metabolism; H. Koh, M.T.), Osaka, and Chemo-Sera-Therapeutics Research Institute, Kumamoto (K.K., Y-i.K.), Japan.
Correspondence to Dr H. Kato, National Cardiovascular Center Research Institute, Fujishirodai-5, Suita, Osaka 565, Japan.
Abstract Tissue factor pathway inhibitor (TFPI), a protease with three tandem Kunitz-type (K1, K2, and K3) domains, inhibits the initial reaction of the TF-mediated coagulation pathway. TFPI occurs in a free and a lipoprotein-associated form in plasma as well as an endothelial cell–associated form on vascular walls. In a previous study we had demonstrated that free-form TFPI activity was lower in hyperlipidemic patients. In the present study we established a new enzyme immunoassay method for measuring free-form TFPI antigen; this new method uses a monoclonal antibody that recognizes the K3 domain of free-form TFPI but not lipoprotein-associated TFPI. Free-form TFPI antigen was significantly lower in hyperlipidemic patients compared with those in normolipidemic individuals. We applied this new method to measure the amount of endothelial cell–associated TFPI, which can be released by heparin injection, as "free-form TFPI." We found that free-form TFPI antigen in plasma was positively correlated with the endothelial cell–associated form. These results indicate that both of these forms of TFPI are in equilibrium in vivo and that our new method can be used for assessing changes in the levels of endothelial cell–associated TFPI antigen and, hence, for assessing thrombotic tendencies in various disease states.
Key Words: enzyme immunoassay • hyperlipidemia • endothelial cell • plasmapheresis • tissue factor pathway inhibitor
This article has been cited by other articles:
 |
|
 |
|
  S. T. Morozowich, B. S. Donahue, and I. J. Welsby Genetics of coagulation: considerations for cardiac surgery. Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 297 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.M Moons, M. Levi, and R. J.G Peters Tissue factor and coronary artery disease Cardiovasc Res, February 1, 2002; 53(2): 313 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mori, H. Wada, Y. Okugawa, S. Tamaki, T. Nakasaki, R. Watanabe, E. C. Gabazza, M. Nishikawa, N. Minami, and H. Shiku Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome Clinical and Applied Thrombosis/Hemostasis, January 1, 2001; 7(1): 5 - 9. [Abstract] [PDF]
|
|
|
|
 |
|
 E. F. Grabowski, A. J. Reininger, P. G. Petteruti, O. Tsukurov, and R. W. Orkin Shear Stress Decreases Endothelial Cell Tissue Factor Activity by Augmenting Secretion of Tissue Factor Pathway Inhibitor Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 157 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Inoue, H. Wada, M. Takagi, M. Yamamuro, K. Mukai, T. Nakasaki, M. Shimura, K. Hiyoyama, H. Deguchi, E. C. Gabazza, et al. Hemostatic Abnormalities in Patients With Thrombotic Complications on Maintenance Hemodialysis Clinical and Applied Thrombosis/Hemostasis, April 1, 2000; 6(2): 100 - 103. [Abstract] [PDF]
|
|
|
|
|
|
A. Kawaguchi, Y. Miyao, T. Noguchi, H. Nonogi, M. Yamagishi, K. Miyatake, Y. Kamikubo, K. Kumeda, M. Tsushima, A. Yamamoto, et al. Intravascular Free Tissue Factor Pathway Inhibitor Is Inversely Correlated With HDL Cholesterol and Postheparin Lipoprotein Lipase but Proportional to Apolipoprotein A-II Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Soejima, H. Ogawa, H. Yasue, K. Kaikita, K. Takazoe, K. Nishiyama, K. Misumi, S. Miyamoto, M. Yoshimura, K. Kugiyama, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J. Am. Coll. Cardiol., October 1, 1999; 34(4): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Dart and J. P.F Chin-Dusting Lipids and the endothelium Cardiovasc Res, August 1, 1999; 43(2): 308 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Soejima, H. Ogawa, H. Yasue, K. Kaikita, K. Nishiyama, K. Misumi, K. Takazoe, Y. Miyao, M. Yoshimura, K. Kugiyama, et al. Heightened Tissue Factor Associated With Tissue Factor Pathway Inhibitor and Prognosis in Patients With Unstable Angina Circulation, June 8, 1999; 99(22): 2908 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moatti, P. Seknadji, C. Galand, O. Poirier, F. Fumeron, S. Desprez, M. Garbarz, D. Dhermy, D. Arveiler, A. Evans, et al. Polymorphisms of the Tissue Factor Pathway Inhibitor (TFPI) Gene in Patients With Acute Coronary Syndromes and in Healthy Subjects : Impact of the V264M Substitution on Plasma Levels of TFPI Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 862 - 869. [Abstract] [Full Text] [PDF]
|
|